語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Renal Pharmacotherapy = Dosage Adjus...
~
Teitelbaum, Isaac.
Renal Pharmacotherapy = Dosage Adjustment of Medications Eliminated by the Kidneys /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Renal Pharmacotherapy/ by Larry K. Golightly, Isaac Teitelbaum, Bonita A. Simendinger, Tyree H. Kiser, Gerard R. Barber, Nancy M. Stolpman.
其他題名:
Dosage Adjustment of Medications Eliminated by the Kidneys /
作者:
Golightly, Larry K.
其他作者:
Stolpman, Nancy M.
面頁冊數:
XXVI, 827 p. 2 illus.online resource. :
Contained By:
Springer Nature eBook
標題:
Drug Resistance. -
電子資源:
https://doi.org/10.1007/978-3-030-58650-8
ISBN:
9783030586508
Renal Pharmacotherapy = Dosage Adjustment of Medications Eliminated by the Kidneys /
Golightly, Larry K.
Renal Pharmacotherapy
Dosage Adjustment of Medications Eliminated by the Kidneys /[electronic resource] :by Larry K. Golightly, Isaac Teitelbaum, Bonita A. Simendinger, Tyree H. Kiser, Gerard R. Barber, Nancy M. Stolpman. - 2nd ed. 2021. - XXVI, 827 p. 2 illus.online resource.
A: Acamprosate to Aztreonam -- B: Bacitracin to Butorphanol -- : Capecitabine to Cycloserine -- D: Dabigatran to Dyphylline -- E: Edetate Calcium Disodium to Exenatide -- F: Famciclovir to Fosfomycin -- H: Hetastarch to Hydroxyurea -- I: Ibandronate to Itraconazole -- K: Kanamycin to Ketorolac -- L: Lacosamide to Lurasidone -- M: Magnesium Citrate to Mycophenolate Mofetil -- N: Nabumetone to Norfloxacin -- O: Ofloxacin to Oxcarbazepine -- P: Paliperidone to Pyridostigmine -- Q: Quinapril to Quinine -- R: Ramipril to Ruxolitinib -- S: Salsalate to Sunitinib -- T: Tadalafil to Trospium -- V: Valacyclovir to Voriconazole -- Z: Zalcitabine to Zonisamide -- Proprietary Name Index.
To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications. This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types. Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.
ISBN: 9783030586508
Standard No.: 10.1007/978-3-030-58650-8doiSubjects--Topical Terms:
782695
Drug Resistance.
LC Class. No.: RC902-918
Dewey Class. No.: 616.61
Renal Pharmacotherapy = Dosage Adjustment of Medications Eliminated by the Kidneys /
LDR
:03098nam a22003855i 4500
001
1051303
003
DE-He213
005
20210924160542.0
007
cr nn 008mamaa
008
220103s2021 sz | s |||| 0|eng d
020
$a
9783030586508
$9
978-3-030-58650-8
024
7
$a
10.1007/978-3-030-58650-8
$2
doi
035
$a
978-3-030-58650-8
050
4
$a
RC902-918
072
7
$a
MJR
$2
bicssc
072
7
$a
MED055000
$2
bisacsh
072
7
$a
MJR
$2
thema
082
0 4
$a
616.61
$2
23
100
1
$a
Golightly, Larry K.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1074940
245
1 0
$a
Renal Pharmacotherapy
$h
[electronic resource] :
$b
Dosage Adjustment of Medications Eliminated by the Kidneys /
$c
by Larry K. Golightly, Isaac Teitelbaum, Bonita A. Simendinger, Tyree H. Kiser, Gerard R. Barber, Nancy M. Stolpman.
250
$a
2nd ed. 2021.
264
1
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2021.
300
$a
XXVI, 827 p. 2 illus.
$b
online resource.
336
$a
text
$b
txt
$2
rdacontent
337
$a
computer
$b
c
$2
rdamedia
338
$a
online resource
$b
cr
$2
rdacarrier
347
$a
text file
$b
PDF
$2
rda
505
0
$a
A: Acamprosate to Aztreonam -- B: Bacitracin to Butorphanol -- : Capecitabine to Cycloserine -- D: Dabigatran to Dyphylline -- E: Edetate Calcium Disodium to Exenatide -- F: Famciclovir to Fosfomycin -- H: Hetastarch to Hydroxyurea -- I: Ibandronate to Itraconazole -- K: Kanamycin to Ketorolac -- L: Lacosamide to Lurasidone -- M: Magnesium Citrate to Mycophenolate Mofetil -- N: Nabumetone to Norfloxacin -- O: Ofloxacin to Oxcarbazepine -- P: Paliperidone to Pyridostigmine -- Q: Quinapril to Quinine -- R: Ramipril to Ruxolitinib -- S: Salsalate to Sunitinib -- T: Tadalafil to Trospium -- V: Valacyclovir to Voriconazole -- Z: Zalcitabine to Zonisamide -- Proprietary Name Index.
520
$a
To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications. This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types. Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.
650
2 4
$a
Drug Resistance.
$3
782695
650
2 4
$a
Pharmaceutical Sciences/Technology.
$3
768561
650
2 4
$a
Internal Medicine.
$3
668583
650
2 4
$a
Pharmacology/Toxicology.
$3
593882
650
0
$a
Drug resistance.
$3
872072
650
0
$a
Pharmaceutical technology.
$3
557391
650
0
$a
Pharmacotherapy.
$3
973587
650
0
$a
Internal medicine.
$3
644638
650
0
$a
Pharmacology.
$3
583819
650
0
$a
Nephrology.
$3
668354
700
1
$a
Stolpman, Nancy M.
$e
author.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1355800
700
1
$a
Barber, Gerard R.
$e
author.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1355799
700
1
$a
Kiser, Tyree H.
$e
author.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1355798
700
1
$a
Simendinger, Bonita A.
$e
author.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1355797
700
1
$a
Teitelbaum, Isaac.
$e
author.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1355796
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer Nature eBook
776
0 8
$i
Printed edition:
$z
9783030586492
776
0 8
$i
Printed edition:
$z
9783030586515
856
4 0
$u
https://doi.org/10.1007/978-3-030-58650-8
912
$a
ZDB-2-SME
912
$a
ZDB-2-SXM
950
$a
Medicine (SpringerNature-11650)
950
$a
Medicine (R0) (SpringerNature-43714)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入